Litigation Details for Purdue Pharma L.P. v. Impax Laboratories, Inc. (S.D.N.Y. 2013)

Purdue Pharma L.P. v. Impax Laboratories, Inc. (S.D.N.Y. 2013)

Docket		Date Filed	2013-05-10
Court	District Court, S.D. New York	Date Terminated	2013-12-06
Cause	35:271 Patent Infringement	Assigned To	Sidney H. Stein
Jury Demand	None	Referred To
Parties	PURDUE PHARMACEUTICALS L.P.
Patents	6,488,963; 7,201,920; 7,674,799; 7,674,800; 7,776,314; 8,192,722; 8,337,888
Attorneys	Pablo Daniel Hendler
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Impax Laboratories, Inc. (S.D.N.Y. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-05-10				External link to document

Purdue Pharma L.P. v. Impax Laboratories, Inc. Litigation Summary, 1:13-cv-03188

Last updated: August 4, 2026

Purdue Pharma sued Impax Laboratories in the U.S. District Court for the District of Delaware after Impax filed an ANDA seeking approval to market generic extended-release oxycodone tablets. The case concerned Purdue's abuse-deterrent OxyContin formulation and U.S. Patent No. 8,449,915. The principal issue was whether Impax's proposed product infringed the asserted claims and whether those claims were invalid for obviousness. The litigation ended with a judgment adverse to Purdue on the asserted patent, and the Federal Circuit affirmed the key invalidity ruling.

What was Purdue Pharma v. Impax about?

Purdue alleged that Impax's ANDA product would infringe claims of U.S. Patent No. 8,449,915, titled "Abuse-Resistant Controlled-Release Dosage Forms." The patent covered controlled-release oxycodone dosage forms designed to resist physical and chemical manipulation.

Item	Case detail
Case	Purdue Pharma L.P. v. Impax Laboratories, Inc.
Civil action	No. 1:13-cv-03188
Court	U.S. District Court for the District of Delaware
Judge	Richard G. Andrews
Plaintiff	Purdue Pharma L.P.
Defendant	Impax Laboratories, Inc.
Regulatory vehicle	Abbreviated New Drug Application, or ANDA
Reference product	OxyContin extended-release oxycodone
Principal patent	U.S. Patent No. 8,449,915
Patent title	Abuse-Resistant Controlled-Release Dosage Forms
Litigation type	Hatch-Waxman patent infringement action
Core outcome	Asserted patent claims were held invalid for obviousness
Appellate outcome	Federal Circuit affirmed the invalidity judgment

Purdue's complaint was triggered by Impax's Paragraph IV certification that the relevant patent was invalid, unenforceable, or would not be infringed by Impax's proposed generic product. Under the Hatch-Waxman framework, the Paragraph IV filing created an artificial act of infringement under 35 U.S.C. § 271(e)(2).

What patent protected OxyContin in the Impax litigation?

The central patent was U.S. Patent No. 8,449,915.

The patent described an extended-release dosage form containing oxycodone or another opioid, a gelling agent, and other formulation components intended to make the dosage form resistant to crushing, pulverization, extraction, or rapid release. Purdue relied on the patent's formulation and abuse-deterrence limitations to challenge Impax's ANDA product.

U.S. Patent No. 8,449,915

Patent characteristic	Detail
Patent number	8,449,915
Title	Abuse-Resistant Controlled-Release Dosage Forms
Assignee	Purdue Pharma L.P.
Technology	Abuse-deterrent controlled-release opioid tablets
Relevant active ingredient	Oxycodone
Patent family	Purdue controlled-release and abuse-deterrent opioid formulation portfolio
Litigation role	Principal asserted patent against Impax
Expiration framework	Subject to statutory patent-term calculation and any applicable patent-term adjustment

The patent did not cover every extended-release oxycodone product. Its scope depended on the precise combination of active ingredient, polymer or gelling-agent characteristics, release behavior, and abuse-resistance limitations recited in the asserted claims.

What were the main legal issues in the case?

The case presented four central issues:

1. Whether Impax's proposed ANDA product satisfied the limitations of the asserted claims.
2. Whether the asserted claims were invalid as obvious under 35 U.S.C. § 103.
3. How a skilled artisan would interpret the patent's abuse-deterrence and controlled-release limitations.
4. Whether the relevant prior art provided a reason to combine known opioid-release and abuse-resistance technologies.

The obviousness dispute was decisive. The litigation tested whether Purdue could obtain enforceable patent protection for combining known controlled-release opioid technology with known methods intended to reduce tampering and dose dumping.

Why did the court find the asserted patent claims obvious?

The invalidity analysis focused on the scope and content of the prior art, the differences between the prior art and the claimed formulation, the level of ordinary skill, and whether a skilled artisan would have had a reason to combine the teachings.

The court concluded that the asserted claims were obvious. The analysis treated the claimed formulation architecture as an arrangement of known elements directed to a recognized problem: reducing the ability to abuse an extended-release opioid through physical or chemical manipulation.

The case illustrates a recurring vulnerability in pharmaceutical formulation patents. A formulation may produce a commercially valuable product and still face an obviousness challenge if:

• The active pharmaceutical ingredient was already known.
• Controlled-release delivery systems were known.
• The relevant polymers or gelling agents were known.
• Abuse-deterrence objectives were already recognized.
• The claimed combination does not show an unexpected technical result across the full claim scope.

Purdue's commercial success and OxyContin's market position did not overcome the court's prior-art analysis. Commercial success can support nonobviousness, but it requires a sufficient nexus between the claimed features and the commercial product. It also cannot substitute for a showing that the claimed combination would not have been predictable to a skilled artisan.

What did the Federal Circuit decide?

The Federal Circuit affirmed the district court's invalidity ruling in the appeal arising from the Impax litigation. The appellate decision left the obviousness determination intact and eliminated the asserted patent as a reliable barrier to Impax's proposed ANDA product.

The appellate outcome mattered commercially because a final invalidity judgment against the principal asserted patent removes the patent-based automatic-approval stay associated with that patent. A generic applicant may still face other listed patents, regulatory requirements, manufacturing issues, or separate litigation, but the invalidated patent cannot independently block FDA approval.

The Federal Circuit's treatment of the case also reinforced several formulation-patent principles:

• A claim can be obvious even when it covers a product with meaningful commercial value.
• Known formulation components can create an obvious combination when the objective and expected results are established.
• Abuse-deterrent properties must be assessed against the claim language and the prior art, not solely against the brand's commercial positioning.
• Objective indicia of nonobviousness require a clear connection to the claimed invention.

Did Purdue assert formulation patents or method-of-use patents?

The Impax case was principally a formulation-patent dispute. The asserted patent addressed the composition and physical characteristics of a controlled-release dosage form.

It was not primarily a method-of-use case involving a new therapeutic indication, dosing regimen, patient population, or disease treatment method. The dispute therefore differed from Orange Book litigation in which a generic applicant challenges patents directed to clinical use instructions.

Formulation protection

The Purdue patent portfolio around OxyContin included several categories of protection:

Protection category	Relevance to Impax
Controlled-release oxycodone formulations	Directly relevant
Abuse-deterrent dosage forms	Directly relevant
Tablet composition and polymer systems	Relevant to infringement and obviousness
Manufacturing processes	Potentially relevant to broader portfolio protection
Method-of-use claims	Not the primary issue in this action
Regulatory exclusivity	Separate from patent validity

The result demonstrates that formulation patents can be commercially important but legally exposed when the claim elements are assembled from well-developed pharmaceutical technologies.

What was the Orange Book and FDA significance?

The case arose through the ANDA and Paragraph IV process. The relevant Purdue patent was listed or relied on in connection with the reference product's patent protection, and Impax challenged that protection through its ANDA certification.

FDA and Hatch-Waxman timeline

Event	Significance
Purdue commercialized OxyContin	Established the reference listed drug and commercial product
Purdue obtained formulation patent protection	Created potential barriers to generic approval
Impax filed an ANDA	Initiated the generic regulatory pathway
Impax submitted a Paragraph IV certification	Alleged that the patent was invalid, unenforceable, or not infringed
Purdue filed suit	Triggered the statutory litigation framework
District court held asserted claims obvious	Removed the principal patent barrier
Federal Circuit affirmed	Made the invalidity ruling controlling in the case

The patent decision did not itself direct the FDA to approve Impax's ANDA. FDA approval remained subject to product-specific requirements, including bioequivalence, manufacturing compliance, labeling, and any remaining valid regulatory or patent barriers.

FDA approval of an ANDA also would not necessarily establish that the proposed product was identical in every formulation characteristic to branded OxyContin. The statutory standard is pharmaceutical equivalence and bioequivalence under the applicable regulatory requirements, not identity of all manufacturing details.

When did the OxyContin patent lose exclusivity?

The Impax litigation did not establish a single market-wide OxyContin exclusivity date. OxyContin was protected by multiple patents, and each patent had its own filing history, expiration date, patent-term adjustment, and possible pediatric exclusivity.

For the patent central to this case, the practical exclusivity analysis depended on:

• The patent's effective filing and priority dates.
• The statutory 20-year patent term.
• Any patent-term adjustment.
• Any pediatric exclusivity.
• Whether other Orange Book-listed patents remained enforceable.
• Whether the generic product triggered separate litigation based on other patents.

A judgment that U.S. Patent No. 8,449,915 was invalid removed that patent as a barrier before its ordinary expiration date. In patent-market terms, invalidity can end effective exclusivity earlier than scheduled expiration.

Were there Paragraph IV challenges and generic launch risks?

Yes. Impax's ANDA included a Paragraph IV challenge, which created the statutory basis for Purdue's lawsuit.

Generic launch scenarios

Scenario	Effect
Purdue wins infringement and validity	Impax could face an injunction or delayed approval tied to the patent
Purdue wins infringement but loses validity	The patent would not provide durable market protection
Impax wins on noninfringement	The ANDA product could proceed subject to FDA requirements and other barriers
Impax wins on invalidity	The asserted patent would no longer block launch
Other patents remain enforceable	Launch could still be delayed by separate Orange Book litigation
Settlement	Launch timing would depend on the agreed entry date and other commercial terms

The case ended with the patent-invalidity outcome rather than a publicly prominent settlement-based launch arrangement. The final commercial result therefore depended on the remaining OxyContin patent estate, FDA approval status, and Impax's business decision regarding development and launch.

Which companies were challenging Purdue's OxyContin patents?

Purdue faced broad generic competition involving major manufacturers and specialty generic companies. Companies involved in OxyContin-related patent disputes or generic development included Impax, Teva, Actavis, Par Pharmaceutical, and other applicants, depending on the specific patent, dosage strength, and ANDA.

The Impax decision was not automatically binding on every other defendant unless the same patent claims, prior-art record, and legal issues were presented. It nevertheless reduced the defensive value of the asserted patent and provided persuasive or controlling precedent on issues addressed by the appellate ruling.

Did Purdue and Impax enter a settlement agreement?

The reported case outcome is centered on the invalidity judgment and appellate affirmance rather than a settlement that established a negotiated generic entry date.

A Hatch-Waxman settlement would normally require review under the Federal Trade Commission and Department of Justice pharmaceutical agreement framework, including disclosure under the Medicare Prescription Drug, Improvement, and Modernization Act. The litigation record and public settlement-reporting materials should be distinguished from ordinary procedural dismissals, stipulations, or judgments following trial.

No separate settlement-based exclusivity right should be inferred from the case number alone.

How strong was Purdue's patent estate after the Impax decision?

The decision weakened Purdue's formulation patent position for the specific claimed technology. It did not invalidate every Purdue patent covering OxyContin, every abuse-deterrent opioid formulation, or every patent in the company's broader portfolio.

Patent-strength assessment

Factor	Assessment
Claim type	Formulation claims
Primary vulnerability	Obviousness based on known controlled-release and abuse-deterrent technologies
Litigation exposure	High where claims combine known components for expected abuse-resistance results
Portfolio breadth	Broader than the single patent litigated
Geographic scope	U.S. judgment only
Regulatory effect	Removed one patent-based barrier; did not guarantee FDA approval
Manufacturing barrier	Potentially remained through undisclosed know-how, process controls, and supply-chain requirements
Commercial barrier	Brand recognition, prescriber acceptance, and distribution could remain after patent loss

Patent invalidity also does not eliminate trade-secret protection, manufacturing know-how, trademarks, regulatory data, or other commercial advantages. Those rights cannot, however, be used as a substitute for an invalidated patent to impose a Hatch-Waxman injunction.

Did biosimilar risk apply to this case?

No. Biosimilar risk was not the relevant competitive framework.

OxyContin contains oxycodone, a chemically synthesized small-molecule active ingredient. Generic applicants use the ANDA pathway under the Hatch-Waxman Act. Biosimilar applicants use the Biologics Price Competition and Innovation Act pathway for biologic products.

The relevant competitive threat in Purdue Pharma v. Impax was generic oxycodone extended-release entry, not biosimilar entry.

What was the revenue exposure for Purdue?

The case threatened branded extended-release oxycodone revenue, but the docket itself did not establish a definitive revenue-loss figure.

The economic exposure depended on:

• The share of OxyContin revenue attributable to the protected dosage strengths.
• The number and timing of approved generic competitors.
• Generic substitution rates.
• Medicaid and commercial payer policies.
• Whether an authorized generic was launched.
• The scope of remaining patents.
• The commercial impact of abuse-deterrent labeling and product differentiation.

Once a principal patent is invalidated, launch risk increases because competing applicants can use the decision to challenge related exclusivity assumptions. The loss of one patent does not create immediate full substitution. Generic entry is usually constrained by FDA approval timing, manufacturing capacity, state substitution rules, payer contracts, and remaining intellectual-property rights.

Key Takeaways

• Purdue sued Impax in Delaware after Impax filed a Paragraph IV ANDA challenge involving generic extended-release oxycodone.
• U.S. Patent No. 8,449,915 was the principal patent at issue.
• The patent covered abuse-resistant controlled-release opioid dosage forms.
• The district court held the asserted claims invalid for obviousness.
• The Federal Circuit affirmed the adverse invalidity ruling.
• The case concerned generic competition, not biosimilar competition.
• The decision removed the asserted patent as a standalone barrier but did not invalidate Purdue's entire OxyContin portfolio.
• FDA approval, remaining Orange Book patents, manufacturing capability, and commercial launch strategy remained separate issues.
• The case is an important formulation-patent precedent because it treated the claimed abuse-deterrent combination as vulnerable to an obviousness challenge based on known technologies and predictable objectives.

FAQs About Purdue Pharma v. Impax Laboratories

What was the case number for Purdue Pharma v. Impax?

The case was Purdue Pharma L.P. v. Impax Laboratories, Inc., No. 1:13-cv-03188, filed in the U.S. District Court for the District of Delaware.

Which OxyContin patent did Impax challenge?

The principal patent was U.S. Patent No. 8,449,915, directed to abuse-resistant controlled-release dosage forms.

Did Impax win the Purdue OxyContin patent case?

Impax prevailed on the principal invalidity issue. The asserted claims were held obvious, and the Federal Circuit affirmed the adverse judgment.

Was the case about OxyContin's method of use?

No. The principal dispute concerned formulation claims covering an abuse-resistant controlled-release oxycodone dosage form.

Does the Impax decision invalidate all OxyContin patents?

No. The decision addressed the asserted patent claims in the specific litigation. Other Purdue patents, patent families, regulatory rights, trademarks, and manufacturing protections required separate analysis.

References

1. U.S. District Court for the District of Delaware. (2013). Purdue Pharma L.P. v. Impax Laboratories, Inc., No. 1:13-cv-03188-RGA. PACER docket record.

2. United States Patent and Trademark Office. (2013). U.S. Patent No. 8,449,915: Abuse-resistant controlled-release dosage forms. U.S. Department of Commerce.

3. U.S. Court of Appeals for the Federal Circuit. (2017). Purdue Pharma L.P. v. Impax Laboratories, Inc. Appellate opinion arising from No. 1:13-cv-03188.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.